0000899243-20-004179.txt : 20200211
0000899243-20-004179.hdr.sgml : 20200211
20200211212330
ACCESSION NUMBER: 0000899243-20-004179
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200211
FILED AS OF DATE: 20200211
DATE AS OF CHANGE: 20200211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MACKAY GEOFFREY
CENTRAL INDEX KEY: 0001741849
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38537
FILM NUMBER: 20599533
MAIL ADDRESS:
STREET 1: C/O AVROBIO, INC.
STREET 2: ONE KENDALL SQ, BLDG. 300, STE. 201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVROBIO, Inc.
CENTRAL INDEX KEY: 0001681087
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 810710585
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BLDG. 300, SUITE 201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 7819626030
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BLDG. 300, SUITE 201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AvroBio, Inc.
DATE OF NAME CHANGE: 20160729
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-11
0
0001681087
AVROBIO, Inc.
AVRO
0001741849
MACKAY GEOFFREY
C/O AVROBIO, INC.
1 KENDALL SQ. BLDG 300, STE 201
CAMBRIDGE
MA
02139
1
1
0
0
See Remarks
Common Stock
2020-02-11
4
S
0
44596
27.3563
D
364927
D
Common Stock
2020-02-11
4
S
0
18404
28.0971
D
346523
D
Common Stock
72604
I
By son of reporting person
Common Stock
72604
I
By daughter of reporting person
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.995, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.35, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
President and Chief Executive Officer
/s/ Steven Avruch, as Attorney-in-Fact
2020-02-11